Consensus statement on prevention and detection of ovarian hyperstimulation syndrome

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 55, Issue 6, 2015, Pages 523-534

  Boothroyd, Clare ^a   Karia, Sonal ^b,c   Andreadis, Natasha ^a   Rombauts, Luk ^d   Johnson, Neil ^e,f   Chapman, Michael ^g,h  

^a Assisted Conception Australia   (Australia)

^b Genea   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d MONASH IVF   (Australia)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f UNIVERSITY OF ADELAIDE   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h IVFAustralia   (Australia)

Author keywords

diagnosis; ovarian hyperstimulation syndrome; prevention

Indexed keywords

ACETYLSALICYLIC ACID; CABERGOLINE; ESTRADIOL; FOLLITROPIN; GLUCONATE CALCIUM; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HISTAMINE; METFORMIN; MUELLERIAN INHIBITING FACTOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR; QUINAGOLIDE; SEROTONIN; VASCULOTROPIN; ANTIDIABETIC AGENT; GONADORELIN;

CONSENSUS; CRUSH SYNDROME; ECHOGRAPHY; EMBRYO TRANSFER; EVIDENCE BASED PRACTICE; FERTILIZATION IN VITRO; FREEZING; HEART MUSCLE FIBROSIS; HUMAN; HYPOTENSION; INTRACYTOPLASMIC SPERM INJECTION; KIDNEY DISEASE; LEAN BODY WEIGHT; LUTEINIZING HORMONE RELEASE; MORBIDITY; MORTALITY; MULTIPLE PREGNANCY; OLIGURIA; OVARIAN RESERVE; OVARY FOLLICLE; OVARY HYPERSTIMULATION; OVARY INSUFFICIENCY; OVULATION; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; RISK REDUCTION; THROMBOEMBOLISM; VALVULAR FIBROSIS; AGONISTS; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; COMPLICATION; CONSENSUS DEVELOPMENT; CRYOPRESERVATION; EVIDENCE BASED MEDICINE; FEMALE; MAMMALIAN EMBRYO; OVARIAN HYPERSTIMULATION SYNDROME; OVARY POLYCYSTIC DISEASE; PRACTICE GUIDELINE; RISK FACTOR; SINGLE EMBRYO TRANSFER;

CONSENSUS; CRYOPRESERVATION; EMBRYO, MAMMALIAN; EVIDENCE-BASED MEDICINE; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OVARIAN HYPERSTIMULATION SYNDROME; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; SINGLE EMBRYO TRANSFER;

EID: 84955188528     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/ajo.12406     Document Type: Review

References (60)

1. Elchalal U, Schenker JG,. The pathophysiology of ovarian hyperstimulation syndrome-views and ideas. Hum Reprod 1997; 12: 1129-1137.
2. Rydberg E, Pederson-Bjergaard K,. Effect of serum gonadotropin and chorionic gonadotropin on the human ovary. JAMA 1943; 121: 1117-1122.
3. The management of Ovarian Hyperstimulation Syndrome. A Green-top guideline. RCOG press at the Royal College of Obstetricians and Gynaecologists, London 2006.
4. Fertility assessment and treatment for people with fertility problems. National Institute for Clinical Excellence (NICE) guideline. RCOG press at the Royal College of Obstetricians and Gynaecologists, London, February 2004.
5. The Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2008; 90 (Suppl 3): S188-S192.
6. Kroon B, Johnson N, Chapman M, et al,. on behalf of the Australasian CREI Consensus Expert Panel of Trial evidence (ACCEPT) group. Fibroids in infertility-consensus statement from ACCEPT. Aust N Z J Obstet Gynaecol 2011; 51: 289-295.
7. Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al,. Incidence and prediction of OHSS in women undergoing Gonadotropin-releasing hormone antagonist in invitro fertilisation cycles. Fertil Steril 2006; 85: 112-120.
8. Mathur R, Valentine AA, Keay SD, et al,. Distinction between early and late OHSS. Fertil Steril 2000; 73: 901-907.
9. Venn A, Hemminki E, Watson L, et al,. Mortality in a cohort of IVF patients. Hum Reprod 2001; 16: 2691-2696.
10. Bratt DDM, Schutte JM, Bernardus RE, et al,. Maternal deaths related to IVF in the Netherlands. Hum Reprod 2010; 25: 1782-1786.
11. Balen A,. Ovarian Hyperstimulation Syndrome. A short report for the HFEA (Human Fertilisation and Embryology Authority) August 2008 www.hfea.gov.uk accessed May 2011
12. Klemetti R, Sevon T, Gissler M, Hemminki E,. Complications of IVF and ovulation induction. Hum Reprod 2005; 20: 3293-3300.
13. Enskog A, Henriksson M, Unander M, et al,. Prospective study of the clinical and laboratory parameters of patients in whom OHSS developed during controlled ovarian hyperstimulation for IVF. Fertil Steril 1999; 71: 808-814.
14. Luke B, Brown MB, Morbeck DE, et al,. Factors associated with OHSS and its effect on ART treatment and outcome. Fertil Steril 2010; 94: 1399-1404.
15. Ludwig M, Finas DF, Al-Hasani S, et al,. Oocyte quality and treatment outcome in ICSI cycles of polycystic ovarian syndrome patients. Hum Reprod 1999; 14: 354-358.
16. Esinler I, Bayar U, Bozdag G, Yarah H,. Outcome of ICSI in patients with polycystic ovarian syndrome or isolated polycystic ovaries. Fertil Steril 2005; 84: 932-937.
17. Rabau E, Serr DM, Masiach S, et al,. Current Concepts in the treatment of anovulation. BMJ 1967; 4: 446-449.
18. Schenker JG, Weinstein D,. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril. 1978; 30: 255-268.
19. Golan A, Ron-el R, Herman A, et al,. Ovarian hyperstimulation syndrome; an update review. Obstet Gynecol Surv 1989; 44: 430-440.
20. Navot D, Bergh PA, Laufer N,. Ovarian hyperstimulation syndro-61me in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992; 58: 249.
21. Rizk B, Aboulghar M,. Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In:, Brinsden P, ed. A textbook of In Vitro Fertilization and Assisted Reproduction. Boca Raton: CRC Press, 1999; 131-155.
22. Humaiden P, Quartarolo J, Papanikolaou E,. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2000; 94: 389-400.
23. Tummon I, Gavrilova-Jordon L, Allemand MC, Session D,. Polycystic ovaries and ovarian hyperstimulation: a systematic review. Acta Obstet Gynaecol Scand 2005; 84: 611-616.
24. Lee TS, Liu CH, Huang CC, et al,. Serum AMH and estradiol levels as predictors of OHSS in ART cycles. Hum Reprod 2008; 23: 160-167.
25. Fukaya T, Murakani T, Tamura M, et al,. Laser vaporisation of ovarian surface in polycystic ovarian disease results in reduced ovarian hyperstimulation and improved pregnancy rates. Am J Obstet Gynecol 1995; 173: 119-125.
26. Danninger B, Brunner M, Obruca A, Feichtinger W,. Prediction of OHSS of baseline ovarian volume prior to stimulation. Hum Reprod 1996; 11: 1597-1599.
27. Maheshwari A, Stojberg L, Bhattacharya S,. Effect of overweight and obesity on ART-a systematic review. Hum Reprod Update 2007; 13: 433-444.
28. Ng EHY, Yeung WSB, Ho PC,. Comparison of two dosages of recombinant human follicle stimulating hormone in Chinese women undergoing controlled ovarian hyperstimulation: prospective randomised double-blind study. HKMJ 2000; 6: 368-374.
29. Yong PYK, Brett S, Baird D, Thong KJ,. A prospective randomised clinical trial comparing 150 IU and 225 IU of recombinant follicle stimulating hormone (Gonal-F) in a fixed dose regimen for controlled ovarian hyperstimulation in invitro fertilization treatment. Fertil Steril 2003; 79: 308-315.
30. Jayaprakasan K, Hopkisson J, Campbell B, et al,. A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. BJOG 2010; 117: 853-862.
31. Pruksananonda K, Suwajanakorn S, Sereepapong W, Virutamasen P,. Comparison of two different fixed doses of follitropin-beta in controlled ovarian hyperstimulation: a prospective randomized double blind clinical trial. J Med Assoc Thai 2004; 87: 1151-1155.
32. Tan SI, Child TJ, Cheung AP, et al,. A randomised double blind multicentre study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon) in women undergoing controlled ovarian hyperstimulation for IVF treatment. J Assist Reprod Genet 2005; 22: 81-88.
33. Al-Inany HG, Youssef MAFM, Aboulghar M, et al,. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews 2011; Issue 5. Art. No.: CD001750. DOI: 10.1002/14651858.CD001750.pub3.
34. Tso LO, Costello MF, Andriolo RB, et al,. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2009; Issue 2. Art. No.: CD006105. DOI: 10.1002/14651858.CD006105.pub2.
35. Varnagy A, Bodis J, Manfai Z, et al,. Low dose aspirin therapy to prevent OHSS. Fertil Steril 2010; 93: 2281-2284.
36. Delvigne A, Rozenberg S,. A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients. Hum Reprod Update 2002; 8: 291-296.
37. Kanthane V, Goswami S, Ghosh S, et al,. Does coasting prevent OHSS without compromising pregnancy outcome? Hum Reprod 2004; 19 (Suppl 6): 121.
38. Youssef MAFM, Al-Inany HG, Aboulghar M, et al,. Recombinant versus urinary HCG for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database Syst Rev 2011; Issue 4. Art. No.:CD003719. doi: 10.1002/14651858. CD003719.pub3.
39. Tsoumpou I, Muglu J, Gelbaya TA, Nardo LG,. Symposium: update on prediction and management of OHSS. Optimal dose of HCG for final oocyte maturation in IVF cycles: absence of evidence Reprod Biomed Online 2009; 19: 52-58.
40. Youssef MAFM, Vander Veen F, Al-Inany HG, et al,. GnRH agonist versus HCG for oocyte triggering in antagonist ART cycles. Cochrane Database Syst Rev 2011; 19: CD008046. doi: 10.1002/14651858.
41. Babayof R, Margalioth EJ, Huleihel M, et al,. Serum inhibin A, VEGF and TNFα levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 2006; 21: 1260-1265.
42. Bodri D, Gullen JJ, Galindo A, et al,. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril 2009; 81: 365-371.
43. Alboulghar M, Evers JLH, Al-Inany HG,. Intravenous albumin for preventing severe OHSS: A Cochrane Review. Hum Reprod 2002; 17: 3017-3032.
44. Youssef MAFM, Al-Inany HG, Evers JLH, Aboulghar M,. Intravenous fluids for the prevention of severe OHSS. Cochrane Database Syst Rev 2011; 16: CD001302. doi: 10.1002/14651858.
45. Ferraretti AP, Gianaroli L, Magli C, et al,. Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety. Hum Reprod 1999; 14: 1457-1460.
46. Youssef MAFM, Van Wely M, Hassan MA, et al,. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles. A systematic review and meta-analysis. Hum Reprod Update 2010; 16: 459-466.
47. Pullan PT,. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy. Int Med J 2009; 39: 213-215.
48. Steward RG, Lan L, Shah A, et al,. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril 2014; 101: 967-973.
49. Venetis CA, Kolibianakis EM, Toulis KA, et al,. Intravenous albumin administration for the prevention of severe OHSS: a systematic review and metaanalysis. Fertil Steril 2011; 95: 188-196.
50. Imbar T, Kol S, Lossos F, et al,. Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support. Hum Reprod 2012; 27: 753-739.
51. Tang H, Hunter T, Hu Y, et al,. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2012; 15: CD008605.pub2.
52. Leitao MS, Moroni RM, Seko LMD, et al,. Cabergoline for the prevention of OHSS: systematic review and meta-analysis of RCTs. Fertil Steril 2014; 101: 664-675.
53. Busso C, Fernandez-Sanchez M, Garcia-Valesco JA, et al,. The non-ergot derived dopamine quinagolide in the prevention of OHSS in IVF patients: a randomized double blind placebo controlled trial. Hum Reprod 2010; 25: 995-1004.
54. Sherwal V, Malik S, Bhatia V,. Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction. J Hum Reprod Sci 2010; 3: 85-90.
55. Chahvar ST, Zosmer A, Caragia A, et al,. Coasting, embryo development and outcomes of blastocyst transfer: a case control study. Reprod Biomed Online 2014; 29: 231-238.
56. Naredi N, Karunakaran S,. Calcium gluconate infusion is as effective as the vascular endothelial growth factor antagonist cabergoline for the prevention of ovarian hyperstimulation syndrome. J Hum Reprod Sci 2013; 6: 248-252.
57. Fatemi HM, Popovic-Todorovic B, Humaidan P, et al,. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol. Fertil Steril 2014; 101: 1008-1011.
58. Griesinger G, Schultz L, Bauer T, et al,. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study. Fertil Steril 2011; 95: 2029-2033.
59. Gurgan T, Demirol A, Guven S, et al,. Intravenous calcium infusion as a novel preventive therapy of ovarian hyperstimulation syndrome for patients with polycystic ovarian syndrome. Fertil Steril 2011; 96: 53-57.
60. Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y,. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reprod Biomed Online 2012; 24: 6-22.